• Buckhardt CS, Goldenberg D, Crofford L, Gerwin R, Gowens S, Jackson K, Kugel P, McCarberg W, Rudin N, Schanberg L, Taylor AG, Taylor J, Turk D. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview (IL): American Pain Society (APS); 2005. 109 p. (Clinical practice guideline; no. 4). [335 references]

This is the current release of the guideline.

These recommendations are presented in abbreviated form. Readers should refer to the text of the guideline document for a detailed discussion of each of the following topics.

Definitions for the type of evidence (I, II, III, IV, V) and the strength and consistency of evidence grades (A, B, C, D, Panel consensus) are provided at the end of the "Major Recommendations" field.

Fibromyalgia Syndrome Diagnosis and Assessment

1. Begin the evaluation of people with fibromyalgia syndrome (FMS) with a complete history and physical examination, focusing on illnesses that may mimic or complicate FMS, such as hypothyroidism or ankylosing spondylitis, or that can occur concurrently with FMS, such as tendonitis, systemic lupus erythematosus, rheumatoid arthritis, or osteoarthritis. The clinician should perform a complete joint examination, manual muscle strength testing, and neurologic examination. (Panel consensus)
2. Base the clinical diagnosis of FMS on the presence of widespread pain, defined as pain in all four body quadrants and axial pain, for at least 3 consecutive months. The only physical examination criterion for the diagnosis of FMS is the presence of excess tenderness to manual palpation of at least 11 of 18 muscle-tendon sites obtained through the manual tender point examination. (B)
3. Focus pain assessment on type and quality of pain, source, location, duration, time course, pain affect, and effects on quality of life. Use self-report as the primary source of pain assessment, and use the same pain measurement tool at subsequent visits. (B)
4. Evaluate the severity of other FMS symptoms, including fatigue, sleep disturbance, and mood and cognitive disturbance. Refer people with suspected mood disorders for formal psychological testing. (Panel consensus)
5. Assess functional status in the initial and subsequent patient visits. Measure the impact of FMS on physical and emotional function and overall quality of life. (Panel consensus)
6. Obtain a complete blood count and conduct erythrocyte sedimentation rate, muscle enzymes, liver function, and thyroid function tests in a new patient with probable FMS. (Panel consensus)

Interventions

7. Begin treatment of FMS by confirming the diagnosis of FMS and explaining what the condition is and what it is not. (Panel consensus) Patient education is critical to optimal management of FMS. (B)
8. Use multiple strategies and include both pharmacologic and nonpharmacologic therapies in the management of FMS. (A)

Pharmacologic Therapies

9. For initial treatment of FMS, prescribe a tricyclic antidepressant for sleep, in particular 10 to 30 mg amitriptyline or cyclobenzaprine at bedtime. (A)
10. Use selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, alone or in combination with tricyclics, for pain relief. (B) The doses of all antidepressants should be individualized and any concurrent mood disturbances treated. (Panel consensus)
11. Do not use non-steroidal anti-inflammatory drugs (NSAIDs) as the primary pain medication for people with FMS. (A) There is no evidence that NSAIDs are effective when used alone to treat FMS patients. NSAIDs, including COX-2 selective agents and acetaminophen, may provide some analgesia when used with other medications. (C)
12. Use tramadol (50 to 100 mg two or three times daily) for pain relief in people with FMS. The dose of tramadol should be increased slowly over time and should be tapered gradually when discontinued. Tramadol can be used alone or in combination with acetaminophen. (B)
13. Use opioids for management of FMS pain only after all other pharmacologic and nonpharmacologic therapies have been exhausted. (Panel consensus)
14. Use sleep and anti-anxiety medications such as trazodone, benzodiazepines, nonbenzodiazepine sedatives, or L-dopa and carbidopa in FMS, especially if sleep disturbances such as restless leg syndrome are prominent. (A)
15. Do not use corticosteroids in the treatment of FMS unless there is concurrent joint, bursa, or tendon inflammation. (A)
16. Ask patients about their use of complementary products and practices and have sufficient knowledge of them to be able to answer questions concerning efficacy and identify possible negative interactions with prescribed treatment. (C)

Nonpharmacologic Therapies

17. Provide all patients with basic information on FMS and treatment options, and educate them about pain management and self-management programs as an initial part of treatment. (A)
18. Incorporate cognitive-behavioral therapy into a multimodality treatment approach to reduce pain, enhance self-efficacy, and improve function. (A)
19. Encourage and support people with FMS to perform moderately intense aerobic exercise (60-75% of age-adjusted maximum heart rate [210 minus the person's age]) two to three times per week. (A) In individuals who are deconditioned, this rate can be achieved with very low levels of exercise.
20. Advise people with FMS to avoid exercise-induced pain by stretching to the point of slight resistance, not to the point of pain. This is especially important in a subgroup of individuals who have joint hypermobility. (B)
21. Begin exercise programs for people with FMS at a level just below their capacity, and progress in frequency, duration, or intensity as their levels of fitness and strength increase. Exercise progression should be slow and gradual, or participants will experience a marked, exercise-induced exacerbation of pain that may lead to discontinuation of the exercise program. (Panel consensus)
22. Encourage people with FMS to perform muscle-strengthening exercise two times per week. (B)
23. Encourage ongoing exercise to maintain exercise-induced gains. (B)
24. Offer clinician-assisted treatments such as clinical hypnosis and biofeedback (B), acupuncture (C), chiropractic manipulation, therapeutic massage (B), and balneotherapy (A), which may be helpful for pain relief.
25. Use multidisciplinary approaches that incorporate two or more strategies to decrease pain and improve function in FMS, especially in people who have not responded to simpler approaches. (A)

Fibromyalgia Syndrome in Children and Adolescents

26. Assessment of pain in children with juvenile FMS (JFMS) should be developmentally based and should include both child and parent components. Include pain history, behavioral observation, physiologic cues, and evaluation of comorbid mood disorders, psychosocial distress, and functional status, including school attendance, for a comprehensive assessment. (Panel consensus)
27. Provide education for the child and family on the diagnosis of JFMS, interrelationship of symptoms, and management of symptoms. Provide education to the child and family on an ongoing basis to increase self-care skills, improve self-efficacy, and enhance understanding of the interrelationships between pain, mood, stress, exercise, and the role of factors concerning the parental and family environment. Include background information regarding the prevalence of pain in children. (Panel consensus)
28. Utilize pharmacologic and nonpharmacologic strategies in the management of JFMS. (Panel consensus)
29. Focus treatment on maximizing function, stressing the importance of regular school attendance. Set functional goals with the child and family. (Panel consensus)
30. Use cognitive-behavioral training (CBT) to reduce pain and psychological disability by enhancing self-efficacy, self-management, and skills for coping with pain. (Panel consensus)
31. Use aerobic exercise to minimize pain, improve sleep quality, enhance self-efficacy and increase positive mood. (Panel consensus)
32. Emphasize sleep hygiene as part of the treatment plan, using both pharmacologic and nonpharmacologic techniques. (Panel consensus)
33. Treat anxiety and depression aggressively with both pharmacologic and nonpharmacologic approaches. (Panel consensus)
34. Fluoxetine should be the first antidepressant agent used to treat depression in children and adolescents; however, all of these medications should be used only with extreme caution and extensive parental education. Psychiatric consultation is recommended. (Panel consensus)
35. Clinicians should focus on the goal of restoring function. The importance of continuing or returning to school cannot be overemphasized, and every effort should be made to maintain and maximize the child's ability to attend school.

Definitions:

Type of Evidence

1. Meta-analysis of multiple well-designed controlled studies
2. Well-designed experimental studies
3. Well-designed, quasi-experimental studies, such as nonrandomized controlled, single-group pre-post, cohort, time series, or matched-case controlled studies
4. Well-designed nonexperimental studies, such as comparative and correlational descriptive and case studies
5. Case reports and clinical examples

Strength and Consistency of Evidence

1. There is evidence of type I or consistent findings from multiple studies of types II, III, or IV.
2. There is evidence of types II, III, or IV, and findings are generally consistent.
3. There is evidence of types II, III, or IV, but findings are inconsistent.
4. There is little or no evidence, or there is type V evidence only.

Panel Consensus: Practice recommended based on the opinions of experts in pain management.

The original guideline document contains algorithms for:

• Assessment of the Patient with Widespread Pain
• Treatment of Fibromyalgia Syndrome

The strength and consistency of the evidence supporting the recommendations ranges from A, which is the strongest evidence to D, which indicates there is little or no evidence, or that only type V (i.e., case reports and clinical examples) exists. In the absence of level A or B evidence, the panel used the available empirical evidence, but based its recommendation primarily on expert judgment. In these instances, the term, "Panel consensus," was used.

The type of evidence and/or expert judgment supporting each recommendation is identified and graded in the "Major Recommendations" field of this summary.

• Buckhardt CS, Goldenberg D, Crofford L, Gerwin R, Gowens S, Jackson K, Kugel P, McCarberg W, Rudin N, Schanberg L, Taylor AG, Taylor J, Turk D. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview (IL): American Pain Society (APS); 2005. 109 p. (Clinical practice guideline; no. 4). [335 references]

Not applicable: The guideline was not adapted from another source.

2005

American Pain Society - Professional Association

The following companies have contributed over the years to a common APS Guidelines Program Fund that is used for the support of all APS evidence-based clinical practice guidelines:

• Abbott Laboratories
• BASF
• Endo Pharmaceuticals Inc.
• Faulding Laboratories
• GlaxoSmithKline
• Hoechst Foundation
• Janssen Pharmaceutica
• Knoll Laboratories
• McNeil Consumer Healthcare
• Merck and Co., Inc.
• Pain Therapeutics, Inc.
• Pharmacia and Upjohn
• Purdue Pharma L.P.
• Roxane Laboratories, Inc.

Fibromyalgia Syndrome Pain Management Guideline Panel (2002-2005)

Panel Members: Carol S. Burckhardt, PhD RN (Co-chair) Professor, Psychiatric Mental Health Nursing, Oregon Health & Science University, School of Nursing, Portland Campus, Portland, OR; Don L. Goldenberg, MD (Co-chair) Chief, Rheumatology Newton-Wellesley Hospital, Newton, MA, Professor of Medicine, Tufts University School of Medicine; Leslie J. Crofford, MD, Associate Professor, Internal Medicine, Rheumatology Division, University of Michigan, School of Medicine, Ann Arbor, MI; Robert Gerwin, MD, Assistant Professor, Neurology, The Johns Hopkins Hospital, East Baltimore Campus, Bethesda, MD; Sue Gowans, PhD PT, University Health Network, Department of Rehabilitation Services, Toronto General Hospital, Toronto, Ontario, Canada; Kenneth C. Jackson II, PharmD, Assistant Professor of Pharmacy Practice--Pain Management, Texas Tech University Health Sciences Center at Amarillo, School of Pharmacy, Lubbock, TX; Pearl Kugel, BBA, Accountant, San Diego, CA; William McCarberg, MD FABPM, Founder, Chronic Pain Management Program, Kaiser Permanente, Escondido, CA; Nathan Jeffrey Rudin, MD, Associate Professor (CHS), Department of Orthopedics and Rehabilitation, University of Wisconsin Medical School Madison, WI; Laura Schanberg, MD, Associate Professor, Pediatrics, Co-chief, Pediatric Rheumatology, Medical Director, Pediatric Pain Evaluation Clinic, Duke University Medical Center, Durham, NC; Ann G. Taylor, EdD RN, Betty Norman Norris Professor of Nursing, Director, Center for the Study of Complementary and Alternative Therapies, University of Virginia Health System, Charlottesville, VA; Janalee Taylor, MSN RN, Clinical Nurse Specialist, Associate Clinical Director, Children's Hospital Medical Center, Cincinnati, OH; Dennis C. Turk, PhD, John and Emma Bonica Professor of Anesthesiology and Pain Research, Department of Anesthesiology, University of Washington, Seattle, WA

Individuals involved in drafting clinical practice guidelines are charged by APS with the responsibility to develop objective, complete, and balanced guidelines. Financial relationships with commercial companies could conflict with the responsibility when the company's products or services are related to the subject of the guideline. To ensure the integrity of APS and the Clinical Practice Guidelines Program, all participants in the development of clinical practice guidelines must submit a Conflict of Interest Disclosure Form to APS prior to participation in any guideline development activity.

All members of the Fibromyalgia Syndrome Pain Management Guideline Panel have submitted a Conflict of Interest Disclosure form, which is on file at the APS national office. In addition, panel members disclosed financial relationships with commercial companies to all other panel members during panel meetings.

Individual panel members presently have or during the past 3 years have had relationships with the following pharmaceutical or biotechnology companies:

Carol S. Burckhardt. Secondary data analysis: Astra Zeneca.

Leslie Crofford. Consultant: Eli Lilly, Pfizer; Speakers' Bureau: Cypress, Forest, Pfizer, Wyeth.

Robert Gerwin. Research support: Allergan, Ferris Manufacturing.

Kenneth Jackson. Consultant: Elan Pharmaceuticals; Research support: Elan Foundation, Merck Foundation; Speakers' Bureau: Merck, Ortho-McNeil, Pharmacia, Purdue Pharma L.P.

William McCarberg. Speakers' Bureau: Endo, Janssen Pharmaceutica, Ligand, Purdue Pharma L.P.

Dennis Turk. Advisory boards: Alpharma, Eli Lilly, Elan Pharmaceuticals, Endo Pharmaceuticals, GlaxoSmithKline, Ligand, Merck, Novartis, Pfizer; Consultant: aaiPharma Inc., Bayer Corporation, Omeros Medical Systems.

Ada Jacox and Carol Spengler, APS consultants. Funding from the APS Guidelines Program Fund.

This is the current release of the guideline.

None available

This NGC summary was completed by ECRI on July 27, 2005. The information was verified by the guideline developer on August 31, 2005. This summary was updated by ECRI Institute on November 9, 2007, following the U.S. Food and Drug Administration advisory on Antidepressant drugs. This summary was updated by ECRI Institute on May 1, 2009 following the U.S. Food and Drug Administration advisory on antiepileptic drugs.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Written requests to reproduce any portion of this guideline may be directed to Managing Editor at the American Pain Society (APS), 4700 W. Lake Avenue, Glenview, IL, 60025-1485.